🎥 An AI Power Player in Healthcare

And it's due for a breakout... ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ 

Note: Is edwardlorilla1986.paxforex@blogger.com your correct email? You haven't clicked in a while and we're concerned you might lose access. Please confirm your address with one click here. Stock of the Week: An AI Power Player in Healthcare SPONSORED PROOF: New One Ticker (Weekly) Payouts A multimillionaire stock trader's research explains how focusing on just one ticker every week has generated payouts up to a rare 2,614% in under 11 days... AND he's brought proof to show the world! [SEE THE PROOF] A Note From Amanda: Regular readers will know that Alpesh is incredibly bullish on the AI sector... and has even begun using AI in his own research. And while he's shared several AI plays here in Stock of the Week that check the boxes of his strict investing system... he's now going public with his absolute favorite way to play the AI boom. This $7 stock is powering the AI market... yet is virtually unknown. This could be your best chance to get in on a life-changing megatrend. Get all the details here. Alpesh Patel As the world's population gets older... and healthcare gets more expensive... the companies working to reduce costs and improve patient outcomes should be on every investor's radar. And the companies doing it with even more efficiency thanks to AI? Well, they could pay the biggest rewards. That's why you're going to like the Stock of the Week I have for you today. [Looking for a Way to Cash In on AI's Global Revolution? Stock Forecasting Champion Says This $10 Play Could Be a Huge Winner.] This company uses AI and machine learning to improve patient outcomes and reduce healthcare costs. It's got phenomenal revenues of $7.7 billion... and a presence in 150 countries. Yet its forecast P/E is a dirt-cheap 17.5. For an AI play in healthcare? That's just plain wrong. This company is trading at 2016 levels... and is overdue for a breakout. Get all the details on the stock - including the ticker - in this week's video. Click here or on the image below to watch it. Happy hunting, Alpesh SPONSORED Investing Wizard Who Turned $37K Into $2.7M in Just 4 Years Makes His Next Big Move He started from nothing and became a multimillionaire... He's now one of the most sought-after trading experts... Yet he operates 858 miles from Wall Street. And now, he's revealing his #1 favorite strategy that targets MASSIVE weekly profits with just one stock ticker. [SEE THE PROOF HERE]   Want more content like this? YES NO   Alpesh Patel Alpesh Patel is an award-winning hedge fund and private equity fund manager, international bestselling author, and entrepreneur. He is the founder and CEO of Praefinium Partners, a Financial Times top FTSE 100 forecaster, and a senior Dealmaker in the U.K.'s Department for International Trade. As a recognized authority on fintech, online trading and venture capital, his past and current client list includes American Express, Merrill Lynch HSBC, Charles Schwab, Goldman Sachs, Barclays... and more.   Was this email forwarded to you? Click here to sign up! You are receiving this email because you subscribed to Manward Financial Digest. To unsubscribe from Manward Financial Digest, click here. Need help with your account? Click here. Have a question or comment for the editor? Click here. Please do not reply to this email as it goes to an unmonitored inbox. To cancel by mail or for any other subscription issues, write us at: Manward Press, LLC | Attn: Support Team | 14 West Mount Vernon Place | Baltimore, MD 21201 North America: 1.800.682.5210 | International: +1.443.353.4263 Website | Privacy Policy Keep the emails you value from falling into your spam folder. Whitelist Manward Financial Digest. © 2023 Manward Press, LLC | All Rights Reserved Nothing published by Manward Press, LLC should be considered personalized investment advice. Although our employees may answer your general customer service questions, they are not licensed under securities laws to address your particular investment situation. No communication by our employees to you should be deemed personalized investment advice. We allow the editors of our publications to recommend securities that they own themselves. However, our policy prohibits editors from exiting a personal trade while the recommendation to subscribers is open. In no circumstance may an editor sell a security before subscribers have a fair opportunity to exit. The length of time an editor must wait after subscribers have been advised to exit a play depends on the type of publication. All other employees and agents must wait 24 hours after publication before trading on a recommendation. Any investments recommended by Manward Press, LLC should be made only after consulting with your investment advisor and only after reviewing the prospectus or financial statements of the company. Protected by copyright laws of the United States and international treaties. The information found on this website may only be used pursuant to the membership or subscription agreement and any reproduction, copying or redistribution (electronic or otherwise, including on the world wide web), in whole or in part, is strictly prohibited without the express written permission of Manward Press, LLC, 14 West Mount Vernon Place, Baltimore, MD 21201.